- Home
- OFS vs BMEA Comparison
OFS vs BMEA Comparison
Compare OFS & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- BMEA
- Stock Information
- Founded
- OFS 2001
- BMEA 2017
- Country
- OFS United States
- BMEA United States
- Employees
- OFS N/A
- BMEA N/A
- Industry
- OFS Finance/Investors Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- OFS Finance
- BMEA Health Care
- Exchange
- OFS Nasdaq
- BMEA Nasdaq
- Market Cap
- OFS 108.5M
- BMEA 125.4M
- IPO Year
- OFS 2012
- BMEA 2021
- Fundamental
- Price
- OFS $8.93
- BMEA $2.71
- Analyst Decision
- OFS
- BMEA Buy
- Analyst Count
- OFS 0
- BMEA 13
- Target Price
- OFS N/A
- BMEA $27.92
- AVG Volume (30 Days)
- OFS 45.0K
- BMEA 600.4K
- Earning Date
- OFS 03-03-2025
- BMEA 05-01-2025
- Dividend Yield
- OFS 15.23%
- BMEA N/A
- EPS Growth
- OFS N/A
- BMEA N/A
- EPS
- OFS 2.12
- BMEA N/A
- Revenue
- OFS $47,964,000.00
- BMEA N/A
- Revenue This Year
- OFS N/A
- BMEA N/A
- Revenue Next Year
- OFS N/A
- BMEA N/A
- P/E Ratio
- OFS $4.21
- BMEA N/A
- Revenue Growth
- OFS N/A
- BMEA N/A
- 52 Week Low
- OFS $7.75
- BMEA $2.50
- 52 Week High
- OFS $10.72
- BMEA $18.40
- Technical
- Relative Strength Index (RSI)
- OFS 69.75
- BMEA 31.13
- Support Level
- OFS $8.21
- BMEA $2.50
- Resistance Level
- OFS $8.94
- BMEA $2.98
- Average True Range (ATR)
- OFS 0.25
- BMEA 0.26
- MACD
- OFS 0.05
- BMEA -0.01
- Stochastic Oscillator
- OFS 97.30
- BMEA 14.38
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.